arrow_back Back to App

Support for Rare Disease Treatment: Tax Credits and CDC Study

This law aims to boost support for rare disease drug development by doubling a tax credit for pharmaceutical companies. Additionally, it mandates the Centers for Disease Control and Prevention (CDC) to conduct a study on improving the tracking and data collection for rare diseases, which could aid in their diagnosis and treatment.
Key points
Companies developing drugs for rare diseases will receive larger tax credits, potentially accelerating the availability of new treatments.
The CDC will conduct a study to improve data collection on rare diseases, which could lead to a better understanding and treatment of these conditions.
The changes aim to improve the lives of individuals with rare diseases by supporting research and drug development.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_2623
Sponsor: Rep. Gottheimer, Josh [D-NJ-5]
Process start date: 2021-04-16
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Cameron’s Law

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_2623.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-04-16.

What are the main provisions?

Key points include:

  • Companies developing drugs for rare diseases will receive larger tax credits, potentially accelerating the availability of new treatments.
  • The CDC will conduct a study to improve data collection on rare diseases, which could lead to a better understanding and treatment of these conditions.
  • The changes aim to improve the lives of individuals with rare diseases by supporting research and drug development.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Gottheimer, Josh [D-NJ-5].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health Taxes